News
On Saturday, the 16th of August, an illegal garbage dump was discovered at Walker Road in the Jedediah Smith portion of .
2h
Asianet Newsable on MSNDynavax’s Experimental Shingles Vaccine Shows Positive Results In Study: Retail Expects Stock Rally To Continue Into Friday
The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in ...
5h
Boing Boing on MSNPeople who get shingles within a year of Covid have doubled reinfection risk and 67 % higher heart attack odds
A study published this week in the peer-reviewed journal Scientific Reports examined the long-term impacts of having shingles ...
Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.
Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...
Modern homeowners are becoming increasingly conscious of energy use—not just for cost savings, but also for environmental responsibility. One of the most overlooked factors influencing home efficiency ...
Chickenpox is an extremely contagious disease, caused by the varicella zoster virus. It has never been on the UK routine vaccination schedule, commonly being seen as a childhood ‘rite of passage’ that ...
Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.
Steve Clisset, a longtime roofer based near Paonia, has been selected to fabricate and install custom metal shingles for a historic restoration project at Fort Yellowstone. His trademarked product, ...
Investing.com -- Dynavax Technologies Corporation (NASDAQ: DVAX) stock soared 8% Thursday after the company announced positive topline results from its Phase 1/2 clinical trial for Z-1018, its ...
Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...
Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results